Cardiovascular Evaluation of the Selective BET Inhibitor, Apabetalone, in ACS Patients With Diabetes: Baseline Characteristics of the BETonMACE CV Outcomes Study

被引：0
|
作者：
Ray, Kausik K. [1 ]
Nicholls, Stephen J. [2 ]
Sweeney, Mike [3 ]
Johansson, Jan O. [3 ]
Toth, Peter P. [4 ]
Ginsberg, Henry [5 ]
Kalantar-Zadeh, Kamyar [6 ]
Schwartz, Gregory G. [7 ]
机构：
[1] Imperial Coll London, Dept Primary Care & Publ Hlth, London, England
[2] South Australian Hlth & Med Rsch Inst, Dept Cardiol, Adelaide, SA, Australia
[3] Resverlogix Inc, Clin Dev, San Francisco, CA USA
[4] CGH Med Ctr, Preventat Cardiol, Chicago, IL USA
[5] Columbia Univ Coll Phys & Surg, Clin & Translat Rsch, 630 W 168th St, New York, NY 10032 USA
[6] Univ Calif Irvine, Nephrol & Hypertens, Orange, CA 92668 USA
[7] Univ Colorado, Sch Med, Aurora, CO USA
来源：
CIRCULATION | 2018年 / 138卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A13189
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry D.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Cummings, Jeffrey L.
    Sweeney, Michael
    Schwartz, Gregory G.
    [J]. AMERICAN HEART JOURNAL, 2019, 217 : 72 - 83
  • [2] BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE trial
    Ray, K. K.
    Nicholls, S. J.
    Sweeney, M.
    Johansson, J.
    Wong, N.
    Kulikowski, E.
    Toth, P.
    Ginsberg, H.
    Kalantar-Zadeh, K.
    Schwartz, G. G.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 2819 - 2819
  • [3] Effect of BET Protein Inhibition With Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE Trial
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsberg, Henry N.
    Johansson, Jan O.
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Schwartz, Gregory G.
    [J]. CIRCULATION, 2019, 140 (25) : E966 - E966
  • [4] DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR APABETALONE ON KIDNEY FUNCTION AND MACE IN POST-ACS PATIENTS WITH ESTIMATED GLOMERULAR FILTRATION RATE BELOW 60 AND DIABETES
    Kalantar-Zadeh, Kam
    Johansson, Jan
    Kulikowski, Ewelina
    Halliday, Christopher
    Lebioda, Ken
    Sweeney, Mike
    Wong, Norman
    Nicholls, Stephen
    Schwartz, Gregory
    Ray, Kausik
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [5] THE BET PROTEIN INHIBITOR APABETALONE REDUCES CONGESTIVE HEART FAILURE INCIDENCE IN PATIENTS WITH ACUTE CORONARY SYNDROME AND DIABETES: RESULTS FROM THE BETONMACE TRIAL
    Sweeney, Michael
    Nicholls, Stephen J.
    Ray, Kausik Kumar
    Buhr, Kevin
    Ginsberg, Henry
    Johansson, Jan
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter
    Wong, Norman
    Schwartz, Gregory G.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (11) : 168 - 168
  • [6] Reduction in the Risk of Major Adverse Cardiovascular Events With Apabetalone, a Bet Protein Inhibitor, in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace Trial
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Ginsberg, Henry
    Johansson, Jan
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Toth, Peter P.
    Wong, Norman
    Sweeney, Michael
    Ray, Kausik K.
    [J]. CIRCULATION, 2020, 142
  • [7] Apabetalone, a selective BET protein inhibitor, reduces ischemic cardiovascular events and hospitalization for heart failure in patients with acute coronary syndrome and type 2 diabetes
    Ray, K. K.
    Nicholls, S. J.
    Buhr, K. A.
    Ginsberg, H. N.
    Kalantar-Zadeh, K.
    Johansson, J. O.
    Kulikowski, E.
    Toth, P. P.
    Wong, N.
    Sweeney, M.
    Schwartz, G. G.
    [J]. EUROPEAN HEART JOURNAL, 2020, 41 : 1425 - 1425
  • [8] EFFECTS OF THE BET-INHIBITOR APABETALONE ON CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND ACUTE CORONARY SYNDROME, ACCORDING TO PRESENCE OR ABSENCE OF CHRONIC KIDNEY DISEASE. A BETONMACE TRIAL REPORT
    Kalantar-Zadeh, Kam
    Ray, Kausik K.
    Nicholls, Stephen J.
    Ginsburg, Henry N.
    Buhr, Kevin A.
    Johansson, Jan
    Kulikowski, Ewelina
    Toth, Peter P.
    Sweeney, Michael
    Schwartz, Gregory G.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 182 - 182
  • [9] BET Protein Inhibitor Apabetalone Suppresses Inflammatory Hyperactivation of Monocytes From Patients With Cardiovascular Disease and Type 2 Diabetes
    Wasiak, Sylwia
    Dzobo, Kim
    Rakai, Brooke
    Kaiser, Yannick
    Versloot, Miranda
    Bahjat, Mahnoush
    Stotz, Stephanie
    Fu, Li
    Sweeney, Michael
    Johansson, Jan
    Wong, Norman
    Stroes, Erik
    Kroon, Jeffrey
    Kulikowski, Ewelina
    [J]. CIRCULATION, 2020, 142
  • [10] THE EPIGENETIC BET-INHIBITOR APABETALONE REDUCES CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES, ACUTE CORONARY SYNDROME AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE TRIAL
    Toth, Peter P.
    Schwartz, Gregory G.
    Nicholls, Stephen J.
    Johansson, Jan
    Ginsberg, Henry
    Kalantar-Zadeh, Kamyar
    Kulikowski, Ewelina
    Wong, Norman C.
    Szarek, Michael
    Sweeney, Michael
    Ray, Kausik Kumar
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 79 (09) : 1104 - 1104
12345